The Banff 2017 Kidney Meeting Report: Revised diagnostic criteria for chronic active T cell–mediated rejection, antibody-mediated rejection, and prospects for integrative endpoints for next-generation clinical trials

M. Haas, A. Loupy, C. Lefaucheur, C. Roufosse, D. Glotz, D. Seron, B. J. Nankivell, P. F. Halloran, R. B. Colvin, Enver Akalin, N. Alachkar, S. Bagnasco, Y. Bouatou, J. U. Becker, L. D. Cornell, J. P.Duong van Huyen, I. W. Gibson, Edward S. Kraus, R. B. Mannon, M. NaesensV. Nickeleit, P. Nickerson, D. L. Segev, H. K. Singh, M. Stegall, P. Randhawa, L. Racusen, K. Solez, M. Mengel

Research output: Contribution to journalArticle

150 Citations (Scopus)

Abstract

The kidney sessions of the 2017 Banff Conference focused on 2 areas: clinical implications of inflammation in areas of interstitial fibrosis and tubular atrophy (i-IFTA) and its relationship to T cell–mediated rejection (TCMR), and the continued evolution of molecular diagnostics, particularly in the diagnosis of antibody-mediated rejection (ABMR). In confirmation of previous studies, it was independently demonstrated by 2 groups that i-IFTA is associated with reduced graft survival. Furthermore, these groups presented that i-IFTA, particularly when involving >25% of sclerotic cortex in association with tubulitis, is often a sequela of acute TCMR in association with underimmunosuppression. The classification was thus revised to include moderate i-IFTA plus moderate or severe tubulitis as diagnostic of chronic active TCMR. Other studies demonstrated that certain molecular classifiers improve diagnosis of ABMR beyond what is possible with histology, C4d, and detection of donor-specific antibodies (DSAs) and that both C4d and validated molecular assays can serve as potential alternatives and/or complements to DSAs in the diagnosis of ABMR. The Banff ABMR criteria are thus updated to include these alternatives. Finally, the present report paves the way for the Banff scheme to be part of an integrative approach for defining surrogate endpoints in next-generation clinical trials.

Original languageEnglish (US)
Pages (from-to)293-307
Number of pages15
JournalAmerican Journal of Transplantation
Volume18
Issue number2
DOIs
StatePublished - Feb 1 2018

Fingerprint

Clinical Trials
Kidney
Atrophy
Antibodies
Fibrosis
Molecular Pathology
Graft Survival
Histology
Biomarkers
Inflammation

Keywords

  • classification systems: Banff classification
  • kidney transplantation/nephrology
  • molecular biology
  • pathology/histopathology
  • rejection
  • translational research/science

ASJC Scopus subject areas

  • Immunology and Allergy
  • Transplantation
  • Pharmacology (medical)

Cite this

The Banff 2017 Kidney Meeting Report : Revised diagnostic criteria for chronic active T cell–mediated rejection, antibody-mediated rejection, and prospects for integrative endpoints for next-generation clinical trials. / Haas, M.; Loupy, A.; Lefaucheur, C.; Roufosse, C.; Glotz, D.; Seron, D.; Nankivell, B. J.; Halloran, P. F.; Colvin, R. B.; Akalin, Enver; Alachkar, N.; Bagnasco, S.; Bouatou, Y.; Becker, J. U.; Cornell, L. D.; van Huyen, J. P.Duong; Gibson, I. W.; Kraus, Edward S.; Mannon, R. B.; Naesens, M.; Nickeleit, V.; Nickerson, P.; Segev, D. L.; Singh, H. K.; Stegall, M.; Randhawa, P.; Racusen, L.; Solez, K.; Mengel, M.

In: American Journal of Transplantation, Vol. 18, No. 2, 01.02.2018, p. 293-307.

Research output: Contribution to journalArticle

Haas, M, Loupy, A, Lefaucheur, C, Roufosse, C, Glotz, D, Seron, D, Nankivell, BJ, Halloran, PF, Colvin, RB, Akalin, E, Alachkar, N, Bagnasco, S, Bouatou, Y, Becker, JU, Cornell, LD, van Huyen, JPD, Gibson, IW, Kraus, ES, Mannon, RB, Naesens, M, Nickeleit, V, Nickerson, P, Segev, DL, Singh, HK, Stegall, M, Randhawa, P, Racusen, L, Solez, K & Mengel, M 2018, 'The Banff 2017 Kidney Meeting Report: Revised diagnostic criteria for chronic active T cell–mediated rejection, antibody-mediated rejection, and prospects for integrative endpoints for next-generation clinical trials', American Journal of Transplantation, vol. 18, no. 2, pp. 293-307. https://doi.org/10.1111/ajt.14625
Haas, M. ; Loupy, A. ; Lefaucheur, C. ; Roufosse, C. ; Glotz, D. ; Seron, D. ; Nankivell, B. J. ; Halloran, P. F. ; Colvin, R. B. ; Akalin, Enver ; Alachkar, N. ; Bagnasco, S. ; Bouatou, Y. ; Becker, J. U. ; Cornell, L. D. ; van Huyen, J. P.Duong ; Gibson, I. W. ; Kraus, Edward S. ; Mannon, R. B. ; Naesens, M. ; Nickeleit, V. ; Nickerson, P. ; Segev, D. L. ; Singh, H. K. ; Stegall, M. ; Randhawa, P. ; Racusen, L. ; Solez, K. ; Mengel, M. / The Banff 2017 Kidney Meeting Report : Revised diagnostic criteria for chronic active T cell–mediated rejection, antibody-mediated rejection, and prospects for integrative endpoints for next-generation clinical trials. In: American Journal of Transplantation. 2018 ; Vol. 18, No. 2. pp. 293-307.
@article{33484e36a5f4434281be9409b6d8a355,
title = "The Banff 2017 Kidney Meeting Report: Revised diagnostic criteria for chronic active T cell–mediated rejection, antibody-mediated rejection, and prospects for integrative endpoints for next-generation clinical trials",
abstract = "The kidney sessions of the 2017 Banff Conference focused on 2 areas: clinical implications of inflammation in areas of interstitial fibrosis and tubular atrophy (i-IFTA) and its relationship to T cell–mediated rejection (TCMR), and the continued evolution of molecular diagnostics, particularly in the diagnosis of antibody-mediated rejection (ABMR). In confirmation of previous studies, it was independently demonstrated by 2 groups that i-IFTA is associated with reduced graft survival. Furthermore, these groups presented that i-IFTA, particularly when involving >25{\%} of sclerotic cortex in association with tubulitis, is often a sequela of acute TCMR in association with underimmunosuppression. The classification was thus revised to include moderate i-IFTA plus moderate or severe tubulitis as diagnostic of chronic active TCMR. Other studies demonstrated that certain molecular classifiers improve diagnosis of ABMR beyond what is possible with histology, C4d, and detection of donor-specific antibodies (DSAs) and that both C4d and validated molecular assays can serve as potential alternatives and/or complements to DSAs in the diagnosis of ABMR. The Banff ABMR criteria are thus updated to include these alternatives. Finally, the present report paves the way for the Banff scheme to be part of an integrative approach for defining surrogate endpoints in next-generation clinical trials.",
keywords = "classification systems: Banff classification, kidney transplantation/nephrology, molecular biology, pathology/histopathology, rejection, translational research/science",
author = "M. Haas and A. Loupy and C. Lefaucheur and C. Roufosse and D. Glotz and D. Seron and Nankivell, {B. J.} and Halloran, {P. F.} and Colvin, {R. B.} and Enver Akalin and N. Alachkar and S. Bagnasco and Y. Bouatou and Becker, {J. U.} and Cornell, {L. D.} and {van Huyen}, {J. P.Duong} and Gibson, {I. W.} and Kraus, {Edward S.} and Mannon, {R. B.} and M. Naesens and V. Nickeleit and P. Nickerson and Segev, {D. L.} and Singh, {H. K.} and M. Stegall and P. Randhawa and L. Racusen and K. Solez and M. Mengel",
year = "2018",
month = "2",
day = "1",
doi = "10.1111/ajt.14625",
language = "English (US)",
volume = "18",
pages = "293--307",
journal = "American Journal of Transplantation",
issn = "1600-6135",
publisher = "Wiley-Blackwell",
number = "2",

}

TY - JOUR

T1 - The Banff 2017 Kidney Meeting Report

T2 - Revised diagnostic criteria for chronic active T cell–mediated rejection, antibody-mediated rejection, and prospects for integrative endpoints for next-generation clinical trials

AU - Haas, M.

AU - Loupy, A.

AU - Lefaucheur, C.

AU - Roufosse, C.

AU - Glotz, D.

AU - Seron, D.

AU - Nankivell, B. J.

AU - Halloran, P. F.

AU - Colvin, R. B.

AU - Akalin, Enver

AU - Alachkar, N.

AU - Bagnasco, S.

AU - Bouatou, Y.

AU - Becker, J. U.

AU - Cornell, L. D.

AU - van Huyen, J. P.Duong

AU - Gibson, I. W.

AU - Kraus, Edward S.

AU - Mannon, R. B.

AU - Naesens, M.

AU - Nickeleit, V.

AU - Nickerson, P.

AU - Segev, D. L.

AU - Singh, H. K.

AU - Stegall, M.

AU - Randhawa, P.

AU - Racusen, L.

AU - Solez, K.

AU - Mengel, M.

PY - 2018/2/1

Y1 - 2018/2/1

N2 - The kidney sessions of the 2017 Banff Conference focused on 2 areas: clinical implications of inflammation in areas of interstitial fibrosis and tubular atrophy (i-IFTA) and its relationship to T cell–mediated rejection (TCMR), and the continued evolution of molecular diagnostics, particularly in the diagnosis of antibody-mediated rejection (ABMR). In confirmation of previous studies, it was independently demonstrated by 2 groups that i-IFTA is associated with reduced graft survival. Furthermore, these groups presented that i-IFTA, particularly when involving >25% of sclerotic cortex in association with tubulitis, is often a sequela of acute TCMR in association with underimmunosuppression. The classification was thus revised to include moderate i-IFTA plus moderate or severe tubulitis as diagnostic of chronic active TCMR. Other studies demonstrated that certain molecular classifiers improve diagnosis of ABMR beyond what is possible with histology, C4d, and detection of donor-specific antibodies (DSAs) and that both C4d and validated molecular assays can serve as potential alternatives and/or complements to DSAs in the diagnosis of ABMR. The Banff ABMR criteria are thus updated to include these alternatives. Finally, the present report paves the way for the Banff scheme to be part of an integrative approach for defining surrogate endpoints in next-generation clinical trials.

AB - The kidney sessions of the 2017 Banff Conference focused on 2 areas: clinical implications of inflammation in areas of interstitial fibrosis and tubular atrophy (i-IFTA) and its relationship to T cell–mediated rejection (TCMR), and the continued evolution of molecular diagnostics, particularly in the diagnosis of antibody-mediated rejection (ABMR). In confirmation of previous studies, it was independently demonstrated by 2 groups that i-IFTA is associated with reduced graft survival. Furthermore, these groups presented that i-IFTA, particularly when involving >25% of sclerotic cortex in association with tubulitis, is often a sequela of acute TCMR in association with underimmunosuppression. The classification was thus revised to include moderate i-IFTA plus moderate or severe tubulitis as diagnostic of chronic active TCMR. Other studies demonstrated that certain molecular classifiers improve diagnosis of ABMR beyond what is possible with histology, C4d, and detection of donor-specific antibodies (DSAs) and that both C4d and validated molecular assays can serve as potential alternatives and/or complements to DSAs in the diagnosis of ABMR. The Banff ABMR criteria are thus updated to include these alternatives. Finally, the present report paves the way for the Banff scheme to be part of an integrative approach for defining surrogate endpoints in next-generation clinical trials.

KW - classification systems: Banff classification

KW - kidney transplantation/nephrology

KW - molecular biology

KW - pathology/histopathology

KW - rejection

KW - translational research/science

UR - http://www.scopus.com/inward/record.url?scp=85040710976&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85040710976&partnerID=8YFLogxK

U2 - 10.1111/ajt.14625

DO - 10.1111/ajt.14625

M3 - Article

C2 - 29243394

AN - SCOPUS:85040710976

VL - 18

SP - 293

EP - 307

JO - American Journal of Transplantation

JF - American Journal of Transplantation

SN - 1600-6135

IS - 2

ER -